Edge Therapeutics (EDGE) vs. Its Competitors Critical Analysis
Edge Therapeutics (NASDAQ: EDGE) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare Edge Therapeutics to related companies based on the strength of its analyst recommendations, earnings, risk, institutional ownership, profitability, dividends and valuation.
This table compares Edge Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Edge Therapeutics Competitors||-5,310.77%||-218.26%||-39.47%|
50.3% of Edge Therapeutics shares are held by institutional investors. Comparatively, 50.0% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 36.2% of Edge Therapeutics shares are held by company insiders. Comparatively, 17.0% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This is a summary of recent ratings and recommmendations for Edge Therapeutics and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Edge Therapeutics Competitors||864||3216||11668||232||2.71|
Edge Therapeutics currently has a consensus target price of $25.50, suggesting a potential upside of 177.48%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 45.10%. Given Edge Therapeutics’ higher probable upside, equities research analysts clearly believe Edge Therapeutics is more favorable than its rivals.
Earnings & Valuation
This table compares Edge Therapeutics and its rivals revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Edge Therapeutics||N/A||-$38.82 million||-5.89|
|Edge Therapeutics Competitors||$284.49 million||$33.78 million||83.75|
Edge Therapeutics’ rivals have higher revenue and earnings than Edge Therapeutics. Edge Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Risk and Volatility
Edge Therapeutics has a beta of 2.52, meaning that its share price is 152% more volatile than the S&P 500. Comparatively, Edge Therapeutics’ rivals have a beta of 5.80, meaning that their average share price is 480% more volatile than the S&P 500.
Edge Therapeutics rivals beat Edge Therapeutics on 7 of the 12 factors compared.
About Edge Therapeutics
Edge Therapeutics, Inc. is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions. The Company’s product candidates utilize its programmable, biodegradable polymer-based development platform (the Precisa Platform), a delivery mechanism that seeks to enable targeted and sustained drug exposure and avoid the dose-limiting side effects associated with the current standards of care. The Company’s product candidates include EG-1962 and EG-1964. EG-1962 is a polymer-based microsphere containing nimodipine suspended in a diluent of sodium hyaluronate was developed using its Precisa development platform to improve patient outcomes following aneurysmal subarachnoid hemorrhage (aSAH).
Receive News & Ratings for Edge Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.